Kiniksa Pharmaceuticals Stock Alpha and Beta Analysis
| KNSA Stock | USD 21.28 0.19 0.90% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Kiniksa Pharmaceuticals. It also helps investors analyze the systematic and unsystematic risks associated with investing in Kiniksa Pharmaceuticals over a specified time horizon. Remember, high Kiniksa Pharmaceuticals' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Kiniksa Pharmaceuticals' market risk premium analysis include:
Beta 1.59 | Alpha (0.47) | Risk 2.91 | Sharpe Ratio (0.12) | Expected Return (0.36) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Kiniksa |
Kiniksa Pharmaceuticals Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Kiniksa Pharmaceuticals market risk premium is the additional return an investor will receive from holding Kiniksa Pharmaceuticals long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Kiniksa Pharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Kiniksa Pharmaceuticals' performance over market.| α | -0.47 | β | 1.59 |
Kiniksa Pharmaceuticals expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Kiniksa Pharmaceuticals' Buy-and-hold return. Our buy-and-hold chart shows how Kiniksa Pharmaceuticals performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Kiniksa Pharmaceuticals Market Price Analysis
Market price analysis indicators help investors to evaluate how Kiniksa Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Kiniksa Pharmaceuticals shares will generate the highest return on investment. By understating and applying Kiniksa Pharmaceuticals stock market price indicators, traders can identify Kiniksa Pharmaceuticals position entry and exit signals to maximize returns.
Kiniksa Pharmaceuticals Return and Market Media
The median price of Kiniksa Pharmaceuticals for the period between Sat, Aug 24, 2024 and Fri, Nov 22, 2024 is 24.99 with a coefficient of variation of 7.51. The daily time series for the period is distributed with a sample standard deviation of 1.86, arithmetic mean of 24.73, and mean deviation of 1.54. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Disposition of 994 shares by Moat Ross of Kiniksa Pharmaceuticals subject to Rule 16b-3 | 08/30/2024 |
2 | Disposition of 14000 shares by Moat Ross of Kiniksa Pharmaceuticals at 8.83 subject to Rule 16b-3 | 09/03/2024 |
3 | Disposition of 10000 shares by Eben Tessari of Kiniksa Pharmaceuticals at 1.59 subject to Rule 16b-3 | 09/23/2024 |
4 | Lion Point Capital LP Has 1.96 Million Stock Holdings in Kiniksa Pharmaceuticals, Ltd. - MarketBeat | 09/27/2024 |
5 | Disposition of 1994 shares by John Paolini of Kiniksa Pharmaceuticals at 26.74 subject to Rule 16b-3 | 09/30/2024 |
6 | Acquisition by Baker Bros. Advisors Lp of 28384 shares of Kiniksa Pharmaceuticals at 24.48 subject to Rule 16b-3 | 10/04/2024 |
7 | Kiniksa Pharmaceuticals COO Eben sells shares worth 456,790 | 10/17/2024 |
8 | What To Expect From Kiniksa Pharmaceuticals International PLC Q3 2024 Earnings | 10/28/2024 |
9 | Kiniksa Pharmaceuticals Q3 2024 Earnings EPS Miss, Revenue Beats Estimates with 112.2 Million | 10/29/2024 |
10 | Earnings call Kiniksa Pharmas Q3 2024 shows strong ARCALYST sales growth | 10/30/2024 |
11 | Kiniksa Pharmaceuticals, Ltd. Q3 2024 Earnings Call Transcript | 10/31/2024 |
12 | Acquisition by Megna Michael R of 175 shares of Kiniksa Pharmaceuticals subject to Rule 16b-3 | 11/01/2024 |
13 | Disposition of 89561 shares by Sanj Patel of Kiniksa Pharmaceuticals at 1.59 subject to Rule 16b-3 | 11/06/2024 |
14 | Disposition of 1303 shares by Levy Richard S of Kiniksa Pharmaceuticals subject to Rule 16b-3 | 11/07/2024 |
15 | Is Kiniksa Pharmaceuticals Top Performing European Stock Heading into 2025 | 11/13/2024 |
16 | Kiniksa Pharmaceuticals COO sells shares valued at 357,680 | 11/20/2024 |
About Kiniksa Pharmaceuticals Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Kiniksa or other stocks. Alpha measures the amount that position in Kiniksa Pharmaceuticals has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2022 | 2023 | 2024 (projected) | Payables Turnover | 5.95 | 6.85 | 7.2 | Days Of Inventory On Hand | 167.86 | 200.97 | 137.66 |
Kiniksa Pharmaceuticals Upcoming Company Events
As portrayed in its financial statements, the presentation of Kiniksa Pharmaceuticals' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Kiniksa Pharmaceuticals' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Kiniksa Pharmaceuticals' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Kiniksa Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Kiniksa Pharmaceuticals' management manipulating its earnings.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 7th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Kiniksa Pharmaceuticals
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Kiniksa Pharmaceuticals Backtesting, Kiniksa Pharmaceuticals Valuation, Kiniksa Pharmaceuticals Correlation, Kiniksa Pharmaceuticals Hype Analysis, Kiniksa Pharmaceuticals Volatility, Kiniksa Pharmaceuticals History and analyze Kiniksa Pharmaceuticals Performance. For information on how to trade Kiniksa Stock refer to our How to Trade Kiniksa Stock guide.You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Kiniksa Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.